Blueprint Medicines (NASDAQ: BPMC) reported Q3 EPS of ($2.20), $0.18 better than the analyst estimate of ($2.38). Revenue for the quarter came in at $56.56 million versus the consensus estimate of $50.66 million.

For earnings history and earnings-related data on Blueprint Medicines (BPMC) click here.